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Background and Objectives Biological raw materials, the basis for cellular thera-
pies such as stem cells, have a significantly greater degree of complexity than
their traditional pharmaceutical counterparts. This can be attributed to the inher-
ent variation of its source – human beings. Currently, cell therapies are made in
small, ad hoc batches, but larger scale production is a prerequisite to meeting
future demand and will require a quality-by-design approach to manufacturing
that will be designed around, or be robust to this variation. Quantification of var-
iation will require understanding of the current baseline and stratification of its
sources.
Materials and Methods Haematopoietic stem cell therapy was chosen as a case
study to explore this variation, and a PRISMA-guided (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) systematic meta-analysis was carried
out for a number of predetermined cell measurements.
Results From this data set, it appears that the extent of variation in therapeutic
dose (in terms of transplanted total nucleated cells and CD34+ cells per kilogram)
for HSCT is between one and four orders of magnitude of the median.
Conclusions This is tolerated under the practice of medicine but would be
unmanageable from a biomanufacturing perspective and raises concerns about
comparable levels of efficacy and treatment. A number of sources that will con-
tribute towards this variation are also reported, as is the direction of travel for 4
greater clarity of the scale of this challenge.
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Context
Biological raw materials, the basis for cellular therapies
(CTs) such as stem cells, have a significantly greater
degree of complexity, sensitivity and plasticity than their
more traditional pharmaceutical counterparts. This can be
attributed to the inherent variation of its source – human
beings.
Currently, stem cell therapies are wrought in small
batches within a hospital/laboratory environment on an
ad hoc basis, regulated as either for homologous use or
minimally manipulated [1]. Larger scale production is a
prerequisite to meeting future clinical demand and will
require a quality-by-design manufacturing process that is
either designed around the inherent biological variation
of the raw material (and its sensitivity during the process)
or be robust to the variation.
A product (the cell in this case) is traditionally manu-
factured to a specification provided by the prescriber. This
would include a number of tolerances – the amount of
change the product can undergo and still remain func-
tional to the predetermined specification. The current tol-
erances for cellular therapies, such as blood-based
haematopoietic stem cells, are based on a minimum and
optimal threshold criteria; for example, in autologous
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HSCT derived from peripheral blood, the minimum is
considered to be 2 9 106 cells/kg bodyweight and the
optimum considered to be 5 9 106 cells/kg bodyweight
[2, 3]. Reducing variation decreases the number of defects
within the product line, and increases its overall quality
at a reduced cost – for cellular therapy, this would mean
maximizing patient longevity and quality of life while
minimizing costs. For CT, this means a consistent, quality
product with a known efficacy at scale. Variation is never
eliminated entirely, and consists of two broad categories;
common cause and special cause variation. Common
cause variation is expected inherent variation as a func-
tion of the raw material and the process involved. Special
cause variation is unexpected variation due to external
factors or unaccounted variables – such as machine fail-
ure causing a product to deviate from tolerance. A pro-
cess with only common cause variation is stable and
predictable.
Quantifying variation will require elucidation of the
baseline variation for the process input/output, and iden-
tification of causes of variation within this process, and
their magnitude. This will identify critical-to-quality attri-
butes and measurands that are key contributing factors
towards the quality and efficacy of the final product and
determine the extent of common and special cause varia-
tion. As Lord Kelvin stated 100 years ago and still holds
true today;
. . .when you can measure what you are speaking
about, and express it in numbers, you know some-
thing about it; but when you cannot express it in
numbers, your knowledge is of a meagre and unsat-
isfactory kind [4].
As pharmaceuticals are defined in terms of grams per
kilogram and purity of active ingredient, so must HSCTs.
Blood-based therapies are characterized by their cell con-
tent, specifically cells per kilogram of patient weight, and
may include total nucleated cells (TNC) and CD34+ cells.
The number of TNCs/product is the more traditional, com-
monly reported parameter for cell dose and represents the
number of cells present excluding red blood cells and
platelets. A more specific characterization uses the cluster
of designation (CD) cell surface marker system. CDs are
involved in critical cellular functions and are therefore
indicative of particular cell types, enabling the identifica-
tion of specific cell types. CD34 is a particular marker
found on haematopoetic progenitor cells (although not all
CD34+ cells are HPCs [5]).
Due to the prevalence of HSCT, it is an ideal exemplar
to benchmark the variation prevalent within a cellular
therapy using a transplant. Additionally, as HSCT is pri-
marily minimally manipulated, it has the potential to act
as a case study to inform the design of processes for
more complex, future biological manufacturing with
higher regulatory thresholds than transplants and also
importantly these materials may also form the starting
material for a therapeutic with a higher regulatory
threshold.
Establishing a baseline
Considering the anecdotal evidence encountered by this
team of the extent of biological variation encountered, a
number of exploratory investigations were devised to
gather the experiences of clinical, industrial and academic
bodies, evaluate the extent of the challenge and inform
the methodology for the next, data-driven steps.
One outcome of these investigations has been the pro-
duction of a generic process map for HSCT (Fig. 1) that
illustrates the universal typical procedures currently fol-
lowed in the hospital/laboratory environment. This dia-
gram illustrates a number of potential sources of
variation, but a greater degree of resolution as to the
extent and distribution of variation within this process is
Fig. 1 A generic process map for haematopoetic stem cell therapy.
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required. As a result a number of clinical and open-
source data sets were identified for data mining – one of
which was ascertained as the medical literature available
in the public domain.
Systematic literature meta-analysis
Although not specifically designed to be utilized in this
manner, or for this particular issue, it was hypothesized
that sufficient information may be present within the
medical literature to complete a preliminary investigation
into the extent of biological variation – sources, collected
cell characteristics, product/dose characteristics, process
specifics and patient outcomes – if the nature of such a
data set and its caveats were understood. The results of
this investigation would identify key areas of interest,
aspects requiring further refinement, and promote critical
process development discussion between industrial, clini-
cal and academic bodies.
This systematic meta-analysis aims to examine the lit-
erature surrounding HSCT for a number of key predeter-
mined variables. The primary objective of this analysis
has been to gain a baseline understanding as to the
extent of biological variation in collected and transplant
cell metrics. Secondary objectives were data-dependant
and included the effect of different processes, indications
and donor/patient characteristics on the aforementioned
cell metrics.
Methodology
This meta-analysis was guided by the principles pre-
scribed by the preferred reporting items for systematic
reviews and meta-analyses statement (PRISMA [6]).
Web of Science, an online database and education
resource, was used to search the literature, using a num-
ber of predetermined keywords, medical search headings
(MeSH) and publication dates (see Table 1). Articles were
restricted to English language unless a native translation
was provided, and only refereed journals were used (con-
ference proceedings were excluded, for example). The
abstracts of the resultant studies were then screened for
likelihood of containing cell data – for example those
that were comparison/outcome studies or clinical trials.
Eligible publications were obtained in full and examined
manually for patient, donor and graft characteristics
guided by Table 2. These characteristics were identified
by previous discussion and mind-mapping. The primary
characteristics were mandatory for studies to pass through
to the data extraction stage. Qualitative data such as
methodology (where recorded) were reduced to single
word/numerical data. The name of the first author and a
unique identification number were used to mark papers
used for future reference.
As a single operator was used to carry out this method-
ology, there may exist a bias, which may have excluded
data-containing studies. A number of these will also be
missing due to insufficient search terms, limitations of
the database used and data published in other languages.
Data were extracted from the full article into a spread-
sheet within Microsoft Excel. Both Excel and IBM SPSS
22.0 (New York) were used for data analysis. Literature
that yielded data was downloaded and stored for future
record alongside its unique identification number.
Results and discussion
The primary output of this meta-analysis was a number
of diagrams that demonstrate the extent of variation in
cell dose found within the literature. There were insuffi-
cient data within the meta-analysis sources to produce a
similar demonstration for cell content of the raw materi-
als. TNC and CD34+ cell count were the most prevalent
cell characteristic reported.
Data drawn from this meta-analysis originated from
multiple global sources, clinical centres, clinicians/surgi-
cal teams, addressing different indications and derived
from different patient and donor demographics. Stratifica-
tion into each of these subsets was not possible due to
the limitations of the literature; however, the data set was
Search Terms
Search
Results
Of which
contained data
A Autologous haematopoetic stem cell therapy (2003–2013) 298 31
B Autologous haematopoetic stem cell therapy (1992–2002) 105 6
C Allogeneic haematopoetic stem cell therapy (2003–2013) 1183 36
D Allogeneic haematopoetic stem cell therapy (1992–2002) 125 4
E Stem cell comparison (2003–2013) 585 9
F Stem cell outcome (2003–2013) 894 40
3190 126
Table 1 Methodology of the Meta-Analysis
search
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scrutinized using Pareto analysis as a factor of location
and indication of study. Pareto analyses are one of the
seven tools of quality in the manufacturing sector, the Pa-
reto rule being commonly referred to as the 80/20 rule –
the observation that 20% of the causes determines 80%
of the problems. In this case, each variable (indication/
country) is plotted in descending order from highest to
lowest contribution with an overlay of percentage cumu-
lative contributions (Fig. 2).
Figure 2 illustrates strong contributions to this data set
from US, German, Chinese and South Korean contribu-
tors. Additionally, the majority of HSCT applications
focused on leukaemia as a target indication. This indica-
tion has led to the identification of a number of substan-
tial clinical data sets that could provide statistically
significant conclusions at a higher resolution.
Figure 3 plots the median TNC count against the med-
ian CD34+ cell count of the given cell dose for a given
literature study. The range in dose given to patients
within each study is represented by the lines spreading
out from these points and has been drawn on a logarith-
mic scale. Fig. 3 is limited to those studies that provided
both median and range data for both TNC count and
CD34+ cell count. This has been further stratified into
autologous and allogeneic therapy, as annotated by the
legend.
This key graph emphasizes that the variation in HSCT
dose in any given study from this data set can be
between one and four orders of magnitude around the
median. To illustrate this using a more traditional exam-
ple, one and four orders of magnitude are the equivalent
of giving a dose of between 1 9 106 cells/kg and
1 9 1010 cells/kg.
This difference in cell dose raises concerns about com-
parable levels of efficacy and treatment within individual
studies and will only complicate attempts to discern the
definitive mode of action for HSCT and the dose/response
relationship. When it comes to larger scale production,
this level of variation would not permit a stable and pre-
dictable manufacturing process and would be unaccept-
able within an equivalent non-biological process.
However, there are a number of considerations regard-
ing this data set that must be taken into account
• Limited data reported in the given studies meant that
stratification according to patient indication or
demographic, and donor metrics such as age, weight
or ethnicity were not possible. To identify any com-
mon and special cause variation due to donor/patient
metrics, further stratification that would allow this
was not possible.
• Cell dose was inconsistently reported as either cells/
kg patient or donor bodyweight. Due to the presence
of paediatric donors/patients, a number of datapoints
may be skewed.
• Methodology was rarely reported, including isolation
technique, patient mobilization drug/regime/condi-
Table 2 Table containing the list of predetermined variables that each study was screened for.
Primary Study Characteristics Secondary Study Characteristics Tertiary Study Characteristics
Number of Donors Donor Mobilisation Drug Named Collection Equipment
Donor Gender Donor Mobilisation Regime Named Processing Equipment
Donor Agea Day of Aspiration/Apheresis Named Analytical Equipment
Donor Weight (kg)a Study Start and End Year CD34 Elucidation Method
Donor Ethnicity Number of Centres involved in
Study
Number of Aspirations/Apheresis procedures
per donor
Number of Patients Country of Study Apheresis flow rate used (ml/min)
Patient Gender Patient Indication Target Apheresis Volume (ml)
Patient Agea Patient Prior Medication Duration of Apheresis
Patient Weight (kg)a Patient Prior Stem Cell Therapy
(Yes/No)
Target Apheresis CD34+ Count
Patient Ethnicity Number of times Donor Complete Blood volume
was processed
Patient Conditioning Number of Grafts/Transfusions per patient
Autologous or Allogeneic Therapy Collection aims for TNC, MNC and CD34+ cell
populations
Source of Stem Cells (marrow, peripheral, cord or mixed) Volume of Collection (ml/kg)
COLLECTED TNC, MNC, CD34+, CFU-GM and viability
(mean, median, standard deviation, upper and lower ranges)
TRANSPLANTED TNC, MNC, CD34+, CFU-GM and viability
(mean, median, standard deviation, upper and lower ranges)
aAt time of procedure.
© 2015 International Society of Blood Transfusion
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Fig. 2 Pareto analyses of meta-analysis
database by geographical location and patient
indication.
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count transplanted in each study.
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tioning and apheresis procedure for example. Con-
sidering the significant effect, these can have on the
cell content of the raw input material; these are
important variables to stratify the effect of differing
processes on the variation.
• Whether fresh or cryopreserved cells were used was
unclear in a number of cases; a further important
stratification in the context of product efficacy and
yield postcryopreservation.
However, the substantial variation encountered in
Fig. 3 can be attributed to a number of broad categories
(albeit at an unknown magnitude and detail).
Sources of variation
• Intra-individual or ‘Within-Person’ Variation – This
is the effect of changes within a specific donor due
to certain internal or external circumstances, such as
changes in blood composition due to seasonality,
circadian rhythm, exercise, extent of specific ill-
nesses and the particular method of isolating the raw
material [7, 8].
• Inter-individual or – ‘Between-Person – This is the
most visually apparent of sources and concerns the
differences between individuals such as age, weight,
lifestyle choice and ethnicity [9–11]. The scarcity of
donor interindividual variables meant that these
were grouped together, which may add to the overall
variation found in Fig. 3.
• Clinical Variation – The previous two sources are vari-
ation expected during both the extraction of HPCs and
their application as a treatment. However, this
assumes that the best practice is being applied, and
where this is not the case – such as when protocols or
techniques are out of date, or if limitations in
resources are apparent – then the difference between
practice used and the best practice available world-
wide is known as ‘unwanted variation’[12, 13]. This is
highly dependent on the skills and resources of the
particular therapeutic centre and is sensitive to geo-
graphical variation (see below). This type of variation
is particularly important from a patient perspective
and the pursuit of clinical trials, as this leads to varia-
tion in the quality of treatment and the potential out-
come and survival chances of the patient [14].
• In Theatre Variation – This instance specifically
applies to bone marrow aspiration, as this requires
an invasive procedure. This source has been sepa-
rately defined to clinical variation as it is specifically
focused on the techniques, tools and methods used
by individual surgeons to isolate and transplant cel-
lular material and has a similar effect on clinical
outcome [15]. For HSCT, this is specifically the isola-
tion techniques of the raw material and the applica-
tion of the final therapeutic via transfusion. Isolation
of raw material is a particularly important step, as
higher the quality of the raw material, the higher the
quality of the product.
• Transplant Type – Depending on the source of the
cells, HSCT is either referred to as autologous or
allogeneic. Autologous HSCT uses starting materials
from the patient and is currently the least expensive
[16]. Allogeneic HSCT uses starting materials from
another matched related or unrelated donor and by
not being patient specific has potential for large-
scale manufacture [17]. Allogeneic sources will tend
to be in a healthier state than an equivalent autolo-
gous source, so this may have implications for cell
quality. However, the allogeneic source must be tis-
sue compatible with the patient.
• Stem Cell Source – The three current main sources
of HSCs are peripheral and cord blood, and bone
marrow. Peripheral blood is the most common
source in Europe (99% autologous, 71% allogeneic),
with bone marrow second (1% autologous, 22% allo-
geneic) and cord blood third (6% allogeneic)[18].
Each has their own distinct advantages and foibles.
Bone marrow has a higher risk to the donor that
increases with age, requiring multiple aspirations
from multiple sites to obtain optimal numbers [19]
and can be painful. Peripheral blood is comparably
more convenient for the donor as apheresis avoids
anaesthesia and theatre. Peripheral blood products
tend to have more CD34+ cells present than compa-
rable bone marrow [20], but this is derived from a
longer procedure than the single extraction session
typical with bone marrow sourced material. Addi-
tionally, peripheral blood has a higher incidence of
acute and chronic graft-versus-host disease [21].
Both marrow and peripheral blood have longer
transplant waiting times than cord blood but allow
for multiple donations, whereas cord blood is a sin-
gle donation. Cord blood has the lowest volume and
cell number (although CD34+ cells from cord blood
have been reported to be more proliferative [22]) but
has a low donor risk and GvHD incidence.
• Operator Variation – Cell culture has been described
as not unlike cooking or gardening [23] and is remi-
niscent of when products were manufactured by arts
transferred by the historical Master and Apprentice
system. HPC product processing is not dissimilar to
this and can be further split into three subcategories.
• Inter-operator variance – This is the differences
between individual operators when applying the
© 2015 International Society of Blood Transfusion
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same methodology (usually following a standard
operating procedure). SOPs define a specific way
of working, and this variation is the difference in
the product due to how these SOPs are interpreted
and carried out between different operators. This
can be a factor of training and inate understand-
ing of the process by the individual.
• Intra-operator variance – This occurs when the
mood or motivation of a particular operator
affects the product [24]. This may be due to a spe-
cific time of day, or life event of the individual
that has a negative or positive affect on their
quality of work or adherence to SOPs.
• The Effect of Learning – This is improvement over
time due to increase in the competency/skill of
the operator [25]. As HSCT products are produced
by particularly manual processes, this is a particu-
lar important source, as many key process steps
are directly controlled by a human operator; dur-
ing separation of blood using a cell processor for
example.
• Human versus Machine Variation – One of the next
steps in controlling operator variance is the use of
automation to reduce the human element and
improve product quality. Machine operators are not
affected by inter- or intra-operator variance. There
are a number of technological hurdles to climb
before fully automated cellular product manufactur-
ing, but robotic operators have been shown to reduce
the effects of variation present in biological pro-
cesses, compared to manual human operators [26].
• Geographical Variation – Due to varying sources of
funding, knowledge and experience of different med-
ical schools, and access to equipment/facilities, there
can be variation in the process method and product
application of the ‘same’ therapy between different
clinical centres within a country, or between coun-
tries [27]. Clinical, surgical and operator variance are
all factors of geographical variation, of which will
be a key factor during and after the roll-out of a
therapeutic to more than one country. Another facet
of geographical variation is the challenges surround
product shelf life and transport of product from ‘fac-
tory’ to clinical location and the effect this will have
on the its efficacy as a result, with cryopreservation
being a particular issue in this instance. In its cur-
rent iteration, HSCT either deals with either fresh
product isolated and transfused within 72 h, chilled
between 1°C and 10°C for transportation or cryopre-
served and transported or stored.
• Regulatory Variation – The difference in require-
ments for a commercial therapeutic (and therefore
the process and standards required to manufacture)
can vary between regulatory bodies.
• Process Variation/Variety of Processes – The variation
inherent to the process, due to the protocol and/or
equipment used, or the variation between differing
processes and could be due to the use of differing
machines, settings on the same machine, how the pro-
cess is designed and how suboptimal the process is. In
engineering, this is assessed by applying an engineer-
ing tolerance to each product attribute (‘tolerance
stacking’), which is the variation a particular measure-
ment cannot exceed otherwise the product is out of
specification. In Rivadeneyra-Espinoza et al.[28], the
enumeration of CD34+ cells within the same labora-
tory, but using different instruments or protocols pro-
duced significantly different numbers of cells.
• Measurement/Measurement system Variation – This
has two key components, precision and accuracy of
the measuring system/equipment. Accuracy repre-
sents how close the measured value is to the ‘true
value’. The true value will often be expressed in the
form of a physical attribute that is time invariant
under controlled conditions. This may be a challenge
for a biological process. Precision represents the
degree to which measurements can be repeated,
under identical conditions, and produce the same
value. Measurement resolution is an additional com-
ponent that must be taken into account with the
increased complexity of biological therapies. This is
a measure of the smallest change that can be made
in the measured material that produces a response in
the measuring system. Measurement variation is a
factor of the equipment and its limitations, the skill
of the operator, the sampling methods and the detec-
tion system. An example of this is the difference
between CD34+ staining and flow cytometry-gating
methods such as ISHAGE, Milan and Norway tech-
niques that can lead to different values being
reported [29].
• Error and Defects – This is a common challenge
within manufacturing and in this instance contrib-
utes to a number of the previous sources of varia-
tion. These are usually as a result of human error
that leads to defects in the product. Examples of this
could be inadvertent mistakes, surprise or a misun-
derstanding leading to a product that does not meet
the specification [30].
Conclusion
On the basis of the public body of knowledge, the extent
of variation in therapeutic dose for HSCT is between one
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and four orders of magnitude of the median. It appears
that this degree of variation is currently tolerated under
the practice of medicine, but would be unmanageable
from a biomanufacturing perspective and could affect the
comparable patient outcome for HSCT. Both medical and
bioengineering fields will need to share their experience
in identifying the sources of variation and the strategies
required to control and bring this variation within a set
tolerance/therapeutic dose. Variation will never be elimi-
nated completely, but it can be controlled to a state
where the differences between products do not affect
patient outcome.
Further work will include continued analysis of the
data set derived from this meta-analysis into autologous,
allogeneic and paediatric subsets, and subsequently focus
on high-quality data sets such as those derived from
large-scale clinical centres and petitioned national health
resources. These will begin to minimize the effect of
some sources of variation (such as operator/process vari-
ety within a single centre), increase the rigour and qual-
ity of reporting and allow further stratification in terms
of donor, patient and methodology. We anticipate that
when this is achieved, it may be possible that the varia-
tion may be reduced from four orders of magnitude as
the effects of a number of sources of variation are mini-
mized.
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